Unicycive Therapeutics Stock Performance
UNCY Stock | USD 1.45 0.01 0.68% |
Unicycive Therapeutics holds a performance score of 12 on a scale of zero to a hundred. The entity has a beta of 0.52, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Unicycive Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Unicycive Therapeutics is expected to be smaller as well. Use Unicycive Therapeutics maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Unicycive Therapeutics.
Risk-Adjusted Performance
12 of 100
Low | High |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Unicycive Up on Positive Hyperphosphatemia Study Update - Zacks Investment Research | 01/24/2024 |
2 | Should Biotechnology Stock Unicycive Therapeutics Inc Be in Your Portfolio Wednesday - InvestorsObserver | 02/07/2024 |
3 | Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate at the Upcoming National Kidney Foundation Spring Clinical Meeting | 02/14/2024 |
4 | Unicycive Therapeutics Averts Nasdaq Delisting Concerns - TipRanks.com - TipRanks | 02/21/2024 |
5 | Unicycive Therapeutics Earns Buy Rating from HC Wainwright - MarketBeat | 03/05/2024 |
6 | Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate | 03/07/2024 |
7 | Unicycive reports progress in kidney injury treatment trial | 03/13/2024 |
8 | Unicycive rises 4 percent on 50M private placement | 03/14/2024 |
9 | Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress | 03/25/2024 |
Begin Period Cash Flow | 7 M |
Unicycive |
Unicycive Therapeutics Relative Risk vs. Return Landscape
If you would invest 87.00 in Unicycive Therapeutics on December 29, 2023 and sell it today you would earn a total of 58.00 from holding Unicycive Therapeutics or generate 66.67% return on investment over 90 days. Unicycive Therapeutics is currently generating 1.0076% in daily expected returns and assumes 6.1545% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Unicycive, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Unicycive Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Unicycive Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Unicycive Therapeutics, and traders can use it to determine the average amount a Unicycive Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1637
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | UNCY | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
6.15 actual daily | 54 54% of assets are less volatile |
Expected Return
1.01 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Unicycive Therapeutics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Unicycive Therapeutics by adding it to a well-diversified portfolio.
Unicycive Therapeutics Fundamentals Growth
Unicycive Stock prices reflect investors' perceptions of the future prospects and financial health of Unicycive Therapeutics, and Unicycive Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Unicycive Stock performance.
Return On Equity | -6.97 | ||||
Return On Asset | -0.83 | ||||
Current Valuation | 36.96 M | ||||
Shares Outstanding | 34.75 M | ||||
Price To Book | 14.87 X | ||||
Price To Sales | 75.17 X | ||||
Revenue | 675 K | ||||
EBITDA | (19.78 M) | ||||
Net Income | (28.07 M) | ||||
Cash Per Share | 0.70 X | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 4.43 X | ||||
Cash Flow From Operations | (19.93 M) | ||||
Earnings Per Share | (1.47) X | ||||
Total Asset | 2.82 M | ||||
Retained Earnings | (34 M) | ||||
About Unicycive Therapeutics Performance
To evaluate Unicycive Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Unicycive Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Unicycive Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Unicycive Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Unicycive's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | 34.86 | 36.61 | |
Return On Assets | (5.77) | (6.06) | |
Return On Equity | 34.89 | 36.63 |
Things to note about Unicycive Therapeutics performance evaluation
Checking the ongoing alerts about Unicycive Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Unicycive Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Unicycive Therapeutics is way too risky over 90 days horizon | |
Unicycive Therapeutics may become a speculative penny stock | |
Unicycive Therapeutics appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 675 K. Net Loss for the year was (28.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Unicycive Therapeutics currently holds about 10.57 M in cash with (19.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. | |
Unicycive Therapeutics has a frail financial position based on the latest SEC disclosures | |
Roughly 18.0% of the company outstanding shares are owned by insiders | |
Latest headline from globenewswire.com: Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress |
- Analyzing Unicycive Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Unicycive Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Unicycive Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Unicycive Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Unicycive Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Unicycive Therapeutics' stock. These opinions can provide insight into Unicycive Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.Note that the Unicycive Therapeutics information on this page should be used as a complementary analysis to other Unicycive Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Unicycive Stock analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Stocks Directory Find actively traded stocks across global markets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Unicycive Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Unicycive Therapeutics. If investors know Unicycive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Unicycive Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share 0.034 | Return On Assets (0.83) | Return On Equity (6.97) |
The market value of Unicycive Therapeutics is measured differently than its book value, which is the value of Unicycive that is recorded on the company's balance sheet. Investors also form their own opinion of Unicycive Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Unicycive Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Unicycive Therapeutics' market value can be influenced by many factors that don't directly affect Unicycive Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Unicycive Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Unicycive Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Unicycive Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.